BRPI0513508B1 - Conjugados de insulina-oligômero, formulações e usos desses - Google Patents

Conjugados de insulina-oligômero, formulações e usos desses Download PDF

Info

Publication number
BRPI0513508B1
BRPI0513508B1 BRPI0513508-7A BRPI0513508A BRPI0513508B1 BR PI0513508 B1 BRPI0513508 B1 BR PI0513508B1 BR PI0513508 A BRPI0513508 A BR PI0513508A BR PI0513508 B1 BRPI0513508 B1 BR PI0513508B1
Authority
BR
Brazil
Prior art keywords
insulin
conjugate
insulin compound
solution
radical
Prior art date
Application number
BRPI0513508-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Radhakrishnan Balasingam
Aggarwal Diti
Ferro Michelle
James Kenneth
B. Malkar Navdeep
A. Miller Mark
Pavliv Leo
Polowy Karen
Puskas Karen
N. Ekwuribe Nnochiri
Original Assignee
Biocon Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Limited filed Critical Biocon Limited
Publication of BRPI0513508A publication Critical patent/BRPI0513508A/pt
Publication of BRPI0513508B1 publication Critical patent/BRPI0513508B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/28—Mercury; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI0513508-7A 2004-07-19 2005-07-19 Conjugados de insulina-oligômero, formulações e usos desses BRPI0513508B1 (pt)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US58905804P 2004-07-19 2004-07-19
US60/589,058 2004-07-19
US61915304P 2004-10-15 2004-10-15
US60/619,153 2004-10-15
US63257804P 2004-12-02 2004-12-02
US60/632,578 2004-12-02
US65583805P 2005-02-24 2005-02-24
US65580305P 2005-02-24 2005-02-24
US60/655,838 2005-02-24
US60/655,803 2005-02-24
PCT/US2005/025644 WO2006014673A2 (en) 2004-07-19 2005-07-19 Insulin-oligomer conjugates, formulations and uses thereof

Publications (2)

Publication Number Publication Date
BRPI0513508A BRPI0513508A (pt) 2008-05-06
BRPI0513508B1 true BRPI0513508B1 (pt) 2021-06-01

Family

ID=35787693

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513508-7A BRPI0513508B1 (pt) 2004-07-19 2005-07-19 Conjugados de insulina-oligômero, formulações e usos desses

Country Status (21)

Country Link
US (6) US7872095B2 (de)
EP (2) EP2626368B1 (de)
JP (3) JP5220410B2 (de)
KR (2) KR101309770B1 (de)
CN (3) CN101027318B (de)
AU (1) AU2005269753B2 (de)
BR (1) BRPI0513508B1 (de)
CA (2) CA2910494C (de)
DK (2) DK1773878T3 (de)
ES (2) ES2535823T3 (de)
HK (1) HK1187826A1 (de)
IL (3) IL180762A (de)
MX (1) MX2007000883A (de)
NO (2) NO345613B1 (de)
NZ (1) NZ553263A (de)
PL (2) PL2626368T3 (de)
PT (2) PT2626368T (de)
RU (2) RU2527893C2 (de)
UA (2) UA91512C2 (de)
WO (1) WO2006014673A2 (de)
ZA (1) ZA200701446B (de)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US7635463B2 (en) * 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
ATE494010T1 (de) * 2002-02-27 2011-01-15 Pharmain Corp Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
EP2085406A1 (de) * 2003-07-25 2009-08-05 ConjuChem Biotechnologies Inc. Langanhaltende Insulinderivate und Verfahren dafür
WO2005112977A2 (en) * 2004-04-23 2005-12-01 Pharmain, Ltd. Compositions for treatment with glucagon-like peptide, and methods of making and using the same
WO2007029238A2 (en) * 2005-09-06 2007-03-15 Oramed Pharmaceuticals, Inc. Methods and compositions for oral administration of proteins
EP2364735A3 (de) 2005-12-16 2012-04-11 Nektar Therapeutics Verzweigte PEG-Kon jugate von GLP-1
AU2006330610B2 (en) 2005-12-19 2012-08-16 Pharmain Corporation Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
US7704977B2 (en) * 2006-04-07 2010-04-27 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
EP2049149B1 (de) 2006-07-31 2015-04-15 Novo Nordisk A/S Pegylierte verlängerte insuline
CN101541830A (zh) * 2006-09-22 2009-09-23 诺沃-诺迪斯克有限公司 蛋白酶抗性的胰岛素类似物
WO2008049711A1 (en) 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins
WO2008132224A2 (en) * 2007-04-30 2008-11-06 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
CN101677944A (zh) * 2007-06-01 2010-03-24 诺沃-诺迪斯克有限公司 稳定的非含水药物组合物
EP2017288A1 (de) * 2007-07-16 2009-01-21 Novo Nordisk A/S Proteasestabilisierte pegylierte Insulinanaloga
WO2009010428A1 (en) 2007-07-16 2009-01-22 Novo Nordisk A/S Protease stabilized, pegylated insulin analogues
DK2180787T3 (da) 2007-08-01 2014-02-03 Univ Pittsburgh Nitrooliesyremodulering af type ii-diabetes
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
AU2008313248B2 (en) * 2007-10-16 2012-04-26 Biocon Limited An orally administerable solid pharmaceutical composition and a process thereof
PT2597103T (pt) 2007-11-16 2017-02-08 Novo Nordisk As Composições farmacêuticas contendo insulina e um péptido insulinotrófico
NZ603812A (en) * 2007-11-20 2014-06-27 Ambrx Inc Modified insulin polypeptides and their uses
US8598311B2 (en) * 2007-11-21 2013-12-03 The University Of The Sciences In Philadelphia Complexation of fatty acid-conjugated molecules with albumin
FR2925333B1 (fr) * 2007-12-19 2012-04-13 Farid Bennis Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
US20090176892A1 (en) 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
WO2009112583A2 (en) * 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
EP2910571B1 (de) 2008-03-18 2016-10-05 Novo Nordisk A/S Proteasestabilisierte, acylierte insulinanaloga
EP3777831B1 (de) 2008-03-26 2023-11-29 Oramed Ltd. Verfahren und zusammensetzungen zur oralen verabreichung von proteinen
CA2729053A1 (en) 2008-05-01 2009-11-05 Bruce A. Freeman Vinyl substituted fatty acids
ES2645588T3 (es) 2008-05-05 2017-12-05 Oramed Ltd. Métodos y composiciones para la administración oral de exenatida
JP2011519928A (ja) * 2008-05-07 2011-07-14 メリオン・リサーチ・Ｉｉｉ・リミテッド ペプチドの組成物及びその調製方法
JP5265762B2 (ja) 2008-05-13 2013-08-14 ユニバーシティ・オブ・カンザス 金属抽出ペプチド（ｍａｐ）タグおよび関連する方法
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
CN102099024B (zh) 2008-06-19 2015-11-25 犹他大学研究基金会 硝化脂质在毒性医疗疗法的副作用的治疗上的用途
EP2300514B1 (de) 2008-07-14 2016-03-23 Biocon Limited Verfahren zur synthese einer weitgehend monodispersen mischung von oligomeren
WO2010033217A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of cd-np peptides
US8846103B2 (en) 2009-01-28 2014-09-30 Smartcells, Inc. Exogenously triggered controlled release materials and uses thereof
ES2791683T3 (es) 2009-01-28 2020-11-05 Smartcells Inc Sistemas a base de conjugados para la administración controlada de fármacos
EP2391217A4 (de) 2009-01-28 2015-05-20 Smartcells Inc Synthetische konjugate und ihre verwendung
US8906850B2 (en) * 2009-01-28 2014-12-09 Smartcells, Inc. Crystalline insulin-conjugates
CA2751854A1 (en) * 2009-02-25 2010-09-02 Merrion Research Iii Limited Composition and drug delivery of bisphosphonates
US9095623B2 (en) * 2009-03-20 2015-08-04 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
WO2010107519A1 (en) * 2009-03-20 2010-09-23 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
US8569231B2 (en) 2009-03-20 2013-10-29 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
WO2010120365A2 (en) * 2009-04-16 2010-10-21 Wu Nian Protein-carrier conjugates
TW201105346A (en) * 2009-07-06 2011-02-16 Sanofi Aventis Deutschland Heat-stable and vibration-stable insulin preparations
EP3045167A1 (de) 2009-07-31 2016-07-20 University of Pittsburgh - Of the Commonwealth System of Higher Education Ketofettsäuren als entzündungshemmende wirkstoffe
WO2011041639A2 (en) 2009-10-02 2011-04-07 Miller Raymond A Heteroatom containing substituted fatty acids
JP2013507414A (ja) 2009-10-13 2013-03-04 エフ．ホフマン−ラ ロシュ アーゲー 神経ペプチド−２受容体（ｙ−２ｒ）アゴニスト
CN102665676B (zh) * 2009-11-02 2015-04-01 诺沃-诺迪斯克有限公司 非共价结合的白蛋白和酰化胰岛素的药物溶液
WO2011084618A2 (en) 2009-12-16 2011-07-14 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
US20110319325A1 (en) * 2010-06-28 2011-12-29 Complexa, Inc. Multi-component pharmaceuticals for treating diabetes
AU2011282977A1 (en) 2010-07-28 2013-02-21 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
CA2805902A1 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Recombinant lectins, binding-site modified lectins and uses thereof
EP2598527A4 (de) 2010-07-28 2014-01-08 Smartcells Inc Rekombinant exprimierte insulinpolypeptide und anwendungen davon
AU2012204213A1 (en) 2011-01-07 2013-06-13 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
CN102614498B (zh) * 2011-01-28 2014-12-17 四川科伦药物研究有限公司 一种胰岛素纳米粒及其制备方法
CN102675452B (zh) * 2011-03-17 2015-09-16 重庆富进生物医药有限公司 具持续降血糖和受体高结合的人胰岛素及类似物的偶联物
RU2606262C2 (ru) * 2011-06-02 2017-01-10 Ханми Сайенс Ко., Лтд. Мультимер непептидильный полимер-инсулин и способ его получения
WO2012171994A1 (en) 2011-06-15 2012-12-20 Novo Nordisk A/S Multi substituted insulins
EP2744491B1 (de) 2011-08-19 2020-07-29 The University of Utah Research Foundation Kombinationstherapie mit nitrierten lipiden und inhibitoren des renin-angiotensin-aldosteron-systems
EP2800579B1 (de) 2012-01-03 2017-08-30 Oramed Ltd. Kapseln enthaltend ölige flüssige zusammensetzungen von kombinierten therapetischen wirkstoffen zur behandlung von diabetes
US10342764B2 (en) 2012-02-01 2019-07-09 Oramed Ltd. Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same
CN104364260B (zh) 2012-04-11 2017-02-22 诺和诺德股份有限公司 胰岛素制剂
WO2013181461A2 (en) 2012-06-01 2013-12-05 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
EP2925341B1 (de) 2012-12-03 2018-01-31 The Board of Regents of the University of Oklahoma Peptidverbindungen und verfahren zur herstellung und verwendung davon
US9096679B2 (en) 2012-12-03 2015-08-04 The Board Of Regents Of The University Of Oklahoma Peptide compounds and methods of production and use thereof
BR112015014510A2 (pt) 2012-12-21 2017-11-21 Sanofi Sa agonistas de glp1/gip duais ou de glp1/gip/glucagon trigonais
EP4215205A1 (de) 2013-01-03 2023-07-26 Oramed Ltd. Verfahren und zusammensetzungen zur behandlung von nafld, lebersteatose und folgen davon
US20200157159A1 (en) 2013-04-16 2020-05-21 The Board Of Regents Of The University Of Oklahoma Peptide compounds and compositions thereof
DK2986309T3 (en) 2013-04-16 2018-05-07 Univ Oklahoma PEPTIME RELATIONS AND PROCEDURES FOR PREPARING AND USING THEREOF
AU2014329567B2 (en) 2013-10-04 2019-07-25 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
ES2676065T3 (es) 2013-10-07 2018-07-16 Novo Nordisk A/S Nuevo derivado de un análogo de la insulina
WO2015084694A2 (en) 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080149A1 (de) 2013-12-13 2016-10-19 Sanofi Duale glp-1-/glucagon-rezeptoragonisten
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
JP6574556B2 (ja) * 2014-08-27 2019-09-11 日東電工株式会社 口腔内フィルム状基剤及び製剤
DK3006045T3 (en) 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
CN104447981B (zh) * 2014-12-25 2015-07-08 重庆浦诺维生物科技有限公司 端羟基聚乙二醇化的人胰岛素及其类似物的偶联物
EP3250225A1 (de) * 2015-01-29 2017-12-06 Novo Nordisk A/S Pharmazeutische zusammensetzung zur oralen insulinverabreichung mit einem tablettenkern und einer polyvinylalkoholbeschichtung
EP3250191B1 (de) 2015-01-29 2024-01-17 Novo Nordisk A/S Tabletten mit glp-1-agonisten und magensaftresistentem überzug
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AU2016289856B2 (en) 2015-07-07 2020-11-26 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
EP3355879A4 (de) 2015-10-02 2019-05-22 Complexa, Inc. Vorbeugung, behandlung und umkehr von erkrankungen mit therapeutisch wirksamen mengen von aktivierten fettsäuren
WO2017060500A1 (en) 2015-10-07 2017-04-13 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
AU2016354479B2 (en) 2015-11-13 2021-10-07 The University Of Massachusetts Bifunctional molecules containing PEG for use in inhibiting cataracts and presbyopia
EP3384935A4 (de) * 2015-12-02 2019-08-21 Hanmi Pharm. Co., Ltd. Proteinkomplex mit fettsäurederivat und herstellungsverfahren dafür
JP6835707B2 (ja) * 2016-04-05 2021-02-24 株式会社Moresco オキサ酸化合物
US10458409B2 (en) * 2016-06-06 2019-10-29 Emerson Climate Technologies, Inc. Compressor having a sleeve guide assembly
MA49116A (fr) 2016-12-16 2020-03-25 Novo Nordisk As Compositions pharmaceutiques contenant de l'insuline
EP3684414A4 (de) * 2017-09-19 2021-06-09 Immunwork Inc. Pharmazeutische konstrukte mit verbesserter bindungsaffinität mit albumin
SI3801526T1 (sl) 2018-05-25 2024-05-31 Cardurion Pharmaceuticals, Inc. Monohidratne in kristalinične oblike 6-((3s, 4s)-4-metil-1-(pirimidin-2-ilmetil)pirolidin-3-il)-3-tetrahidropiran-4- il-7h-imidazo (1.5 - a) pirazin-8-ona
US20210220443A1 (en) * 2018-06-18 2021-07-22 Biocon Limited Method and use of controlling postprandial glucose levels in a subject
US20220064213A1 (en) * 2019-01-10 2022-03-03 Biocon Limited Preparative crystallization of recombinant human insulin

Family Cites Families (292)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2626228A (en) * 1945-05-17 1953-01-20 Novo Terapeutisk Labor As Method of producing crystalline insulin
US2882203A (en) * 1951-06-26 1959-04-14 Novo Terapeutisk Labor As Injectable insulin preparation with protracted effect
DK78069C (da) * 1952-06-23 1954-09-06 Novo Terapeutisk Labor As Fremgangsmåde til fremstilling af krystallinsk insulin.
US2789080A (en) * 1952-08-14 1957-04-16 Christensen Henry Marinus Insulin-albumin compositions
US2849370A (en) * 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
US3102077A (en) * 1953-08-19 1963-08-27 Christensen Henry Marinus Preparation of insulin containing 2.75 to 8 percent zinc content
US2819999A (en) * 1953-11-13 1958-01-14 Novo Terapeutisk Labor As Process for crystallization of insulin using freeze dried insulin as seeding material
US2799622A (en) 1953-11-14 1957-07-16 Novo Terapeutisk Labor As Process of producing insulin crystals of substantially uniform size and compositions thereof
US3058885A (en) * 1957-06-08 1962-10-16 Novo Terapeutisk Labor As Process for treatment of insulin crystals and for production of insulin preparationstherefrom
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
US3014842A (en) * 1957-08-10 1961-12-26 Novo Terapeutish Lab A S Injectable bovine insulin crystal suspensions and process of producing same
US3091573A (en) 1958-05-12 1963-05-28 Novo Terapeutisk Labor As Quick acting insulin preparation
US3256153A (en) * 1963-02-08 1966-06-14 Smith Kline French Lab Method of stabilizing wax-fat coating materials and product thereof
US4003792A (en) * 1967-07-01 1977-01-18 Miles Laboratories, Inc. Conjugates of acid polysaccharides and complex organic substances
US3950517A (en) * 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
GB1381274A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3919411A (en) 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
US4044196A (en) * 1972-03-30 1977-08-23 Bayer Aktiengesellschaft Crosslinked copolymers of α,β-olefinically unsaturated dicarboxylic anhydrides
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
FR2408387A2 (fr) * 1975-06-30 1979-06-08 Oreal Compositions a base de dispersions aqueuses de spherules lipidiques
US4087390A (en) * 1977-02-02 1978-05-02 Eli Lilly And Company Somatostatin analogs and intermediates thereto
US4093574A (en) 1977-02-02 1978-06-06 Eli Lilly And Company Somatostatin analogs and intermediates thereto
US4087930A (en) * 1976-10-20 1978-05-09 O. F. Mossberg & Sons, Inc. Magazine cap retaining means for tubular magazine firearms
US4223163A (en) * 1976-12-10 1980-09-16 The Procter & Gamble Company Process for making ethoxylated fatty alcohols with narrow polyethoxy chain distribution
JPS53116315A (en) * 1977-03-17 1978-10-11 Ueno Seiyaku Oyo Kenkyujo Kk Powder or granular containing improved sorbinic acid
US4100117A (en) * 1977-04-21 1978-07-11 Eli Lilly And Company Somatostatin analogs and intermediates thereto
US4253998A (en) * 1979-03-09 1981-03-03 American Home Products Corporation Peptides related to somatostatin
JPS54148722A (en) * 1978-05-12 1979-11-21 Takeda Chem Ind Ltd Nonapeptide and its preparation
US4277394A (en) 1979-04-23 1981-07-07 Takeda Chemical Industries, Ltd Tetrapeptidehydrazide derivatives
GB2051574B (en) 1979-05-10 1984-01-18 Kyoto Pharma Ind Adjuvant for promoting absorption of pharmacologically active substances through the rectum
US4469681A (en) 1979-07-31 1984-09-04 The Rockefeller University Method and system for the controlled release of biologically active substances to a body fluid
US4348387A (en) * 1979-07-31 1982-09-07 The Rockefeller University Method and system for the controlled release of biologically active substances to a body fluid
FR2465486A1 (fr) 1979-09-21 1981-03-27 Roussel Uclaf Nouvelle application utilisant la lh-rh ou des agonistes
JPS5692846A (en) 1979-12-27 1981-07-27 Takeda Chem Ind Ltd Tetrapeptide derivative and its preparation
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
IT1144743B (it) * 1981-07-09 1986-10-29 Mario Cane Apparecchio infusore di insulina perfezionato
US4654324A (en) * 1981-08-27 1987-03-31 Eli Lilly And Company Human proinsulin pharmaceutical formulations
US4476113A (en) * 1981-10-27 1984-10-09 Union Oil Company Of California Stabilized fumigant composition comprising an aqueous solution of ammonia, hydrogen sulfide, carbon disulfide and sulfur
FI78616C (fi) 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US4698264A (en) * 1982-08-02 1987-10-06 Durkee Industrial Foods, Corp. Particulate composition and process for making same
IL68769A (en) * 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
US4602043A (en) * 1983-07-18 1986-07-22 Technology Unlimited Inc. Treatment for hypoglycemia
JPS6032714A (ja) * 1983-08-01 1985-02-19 Teijin Ltd 鼻腔粘膜に適用するための安定化された粉末状薬学的組成物
JPS60130003A (ja) 1983-12-16 1985-07-11 日本特殊陶業株式会社 高周波用誘電体磁器組成物
US4717566A (en) 1984-03-19 1988-01-05 Alza Corporation Dosage system and method of using same
US4684524A (en) 1984-03-19 1987-08-04 Alza Corporation Rate controlled dispenser for administering beneficial agent
US4704394A (en) * 1984-04-25 1987-11-03 Technology Unlimited, Inc. Treatment for hyperactivity
US4849405A (en) * 1984-05-09 1989-07-18 Synthetic Blood Corporation Oral insulin and a method of making the same
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4863896A (en) 1984-05-03 1989-09-05 Technology Unlimited, Inc. Diabetic control by combined insulin forms
US4761287A (en) 1984-05-03 1988-08-02 Technology Unlimited, Inc. Diabetes control by serotonin
US4963526A (en) * 1984-05-09 1990-10-16 Synthetic Blood Corporation Oral insulin and a method of making the same
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
US4622392A (en) * 1984-06-21 1986-11-11 Health Research Inc. (Roswell Park Division) Thiophospholipid conjugates of antitumor agents
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US4797288A (en) * 1984-10-05 1989-01-10 Warner-Lambert Company Novel drug delivery system
US4946828A (en) * 1985-03-12 1990-08-07 Novo Nordisk A/S Novel insulin peptides
US5157021A (en) 1985-03-15 1992-10-20 Novo Nordisk A/S Insulin derivatives and pharmaceutical preparations containing these derivatives
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
SE457326B (sv) * 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
CA1257199A (en) * 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
ZA877505B (en) 1986-10-14 1989-05-30 Lilly Co Eli Process for transforming a human insulin precursor to human insulin
GB8706313D0 (en) * 1987-03-17 1987-04-23 Health Lab Service Board Treatment & prevention of viral infections
US4764592A (en) * 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production
US5093198A (en) 1987-06-19 1992-03-03 Temple University Adjuvant-enhanced sustained release composition and method for making
US4822337A (en) * 1987-06-22 1989-04-18 Stanley Newhouse Insulin delivery method and apparatus
DE3721721C1 (de) 1987-07-01 1988-06-09 Hoechst Ag Verfahren zur Umhuellung von Granulaten
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5034415A (en) * 1987-08-07 1991-07-23 Century Laboratories, Inc. Treatment of diabetes mellitus
JPH01308231A (ja) * 1988-06-03 1989-12-12 Takeda Chem Ind Ltd 安定化された医薬組成物および製造法
US5055300A (en) * 1988-06-17 1991-10-08 Basic Bio Systems, Inc. Time release protein
DK336188D0 (da) 1988-06-20 1988-06-20 Nordisk Gentofte Propeptider
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5162430A (en) 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5306500A (en) 1988-11-21 1994-04-26 Collagen Corporation Method of augmenting tissue with collagen-polymer conjugates
JPH04502465A (ja) * 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ ヒトインシュリン類似物質
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5089261A (en) * 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
US5182258A (en) * 1989-03-20 1993-01-26 Orbon Corporation Systemic delivery of polypeptides through the eye
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5286637A (en) 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5650388A (en) 1989-11-22 1997-07-22 Enzon, Inc. Fractionated polyalkylene oxide-conjugated hemoglobin solutions
US5312808A (en) 1989-11-22 1994-05-17 Enzon, Inc. Fractionation of polyalkylene oxide-conjugated hemoglobin solutions
CA2030174C (en) 1990-01-10 1996-12-24 Anthony H. Cincotta Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US5468727A (en) 1990-12-13 1995-11-21 Board Of Regents, The University Of Texas System Methods of normalizing metabolic parameters in diabetics
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
WO1992018147A1 (en) * 1991-04-19 1992-10-29 Affinity Biotech, Inc. Convertible microemulsion formulations
FR2675807B1 (fr) 1991-04-23 1994-07-01 Medgenix Group Sa Conjugue de calcitonine et de polyethylene glycol.
US5304473A (en) 1991-06-11 1994-04-19 Eli Lilly And Company A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
ATE189124T1 (de) 1991-07-02 2000-02-15 Inhale Inc Verfahren und vorrichtung zum abgeben von medikamenten in aerosolform
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
ATE144137T1 (de) 1991-07-26 1996-11-15 Smithkline Beecham Corp W/o mikroemulsionen
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US5693769A (en) 1991-12-13 1997-12-02 Transcell Technologies, Inc. Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5320094A (en) 1992-01-10 1994-06-14 The Johns Hopkins University Method of administering insulin
US5876754A (en) * 1992-01-17 1999-03-02 Alfatec-Pharma Gmbh Solid bodies containing active substances and a structure consisting of hydrophilic macromolecules, plus a method of producing such bodies
WO1993013757A1 (de) 1992-01-17 1993-07-22 Alfatec-Pharma Gmbh Wirkstoff-enthaltende festkörper mit einem gerüst aus hydrophilen makromolekülen und verfahren zu ihrer herstellung
GB9212511D0 (en) 1992-06-12 1992-07-22 Cortecs Ltd Pharmaceutical compositions
US5262172A (en) 1992-06-19 1993-11-16 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing buffered bile acids
US5415872A (en) * 1992-06-22 1995-05-16 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing salts of bile acids
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6509006B1 (en) 1992-07-08 2003-01-21 Inhale Therapeutic Systems, Inc. Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
US5420108A (en) 1992-09-14 1995-05-30 Shohet; Isaac H. Method of controlling diabetes mellitus
BR9307141A (pt) 1992-09-29 1999-03-30 Inhale Therapeutic Syst Processo para a liberação sistência pulsátil de um fragmento ativo de hormônio de paratiróide (PTH) para um hospedeiro mamífero e para um paciente e composição farmacêutica
US6093391A (en) 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
GB9316895D0 (en) 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
US5298643A (en) 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US5349001A (en) 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5364838A (en) * 1993-01-29 1994-11-15 Miris Medical Corporation Method of administration of insulin
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5298410A (en) 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
IS1796B (is) 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US20010003739A1 (en) * 1993-06-24 2001-06-14 Astrazeneca Ab Systemic administration of a therapeutic preparation
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US5747445A (en) 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US5534488A (en) * 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
BR9407508A (pt) 1993-09-17 1997-01-07 Novo Nordisk As Derivado de insulina composição farmaceutica e processo para o tratamento de diabete em um paciente com necessidade deste tratamento
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5707648A (en) 1993-11-17 1998-01-13 Lds Technologies, Inc. Transparent liquid for encapsulated drug delivery
ATE264096T1 (de) 1994-03-07 2004-04-15 Nektar Therapeutics Verfahren und mittel zur verabreichung von insulin über die lunge
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
GB9406094D0 (en) 1994-03-28 1994-05-18 Univ Nottingham And University Polymer microspheres and a method of production thereof
JP4043046B2 (ja) 1994-05-10 2008-02-06 ニコックス エス エイ 消炎、鎮痛および抗血栓活性を有するニトロ化合物およびそれらの組成物
DE69533987T2 (de) 1994-05-20 2006-03-16 Hisamitsu Pharmaceutical Co., Inc., Tosu Protein oder polypeptid, verfahren zur seiner herstellung und entsprechende zwischenprodukte
US5504188A (en) 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US6165976A (en) 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
US5730990A (en) 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5840891A (en) 1994-07-28 1998-11-24 Syntex (U.S.A.) Inc. 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative
US5543414A (en) * 1994-07-28 1996-08-06 Syntex (Usa) Inc. Achiral amino acid acyl esters of ganciclovir and its derivatives
PE32296A1 (es) * 1994-07-28 1996-08-07 Hoffmann La Roche Ester de l-monovalina derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il) metoxi-1,3-propandiol y sus sales farmaceuticamente aceptables
GB9417524D0 (en) 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
NZ293163A (en) 1994-09-21 1998-09-24 Inhale Therapeutic Syst Inhalation medicament disperser, aerosol from high pressure gas entrainment of fluidised powder drawn from receptacle feed tube
CN1080575C (zh) * 1994-10-14 2002-03-13 蛋白质传送股份有限公司 结合稳定的多肽组合物、其治疗、诊断制剂及其制备和使用方法
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
AU697440B2 (en) 1994-12-07 1998-10-08 Novozymes A/S Polypeptide with reduced allergenicity
GB9424902D0 (en) 1994-12-09 1995-02-08 Cortecs Ltd Solubilisation Aids
SE9404468D0 (sv) 1994-12-22 1994-12-22 Astra Ab Powder formulations
US5843866A (en) 1994-12-30 1998-12-01 Hampshire Chemical Corp. Pesticidal compositions comprising solutions of polyurea and/or polyurethane
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5907030A (en) 1995-01-25 1999-05-25 University Of Southern California Method and compositions for lipidization of hydrophilic molecules
KR0150565B1 (ko) 1995-02-15 1998-08-17 김정재 유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조방법
US6251856B1 (en) * 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
YU18596A (sh) 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
US5606038A (en) 1995-04-10 1997-02-25 Competitive Technologies, Inc. Amphiphilic polyene macrolide antibiotic compounds
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
DE741187T1 (de) 1995-05-05 1997-04-30 Hoffmann La Roche Rekombinante Obesitäts-(OB)-Proteine
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US5704910A (en) 1995-06-05 1998-01-06 Nephros Therapeutics, Inc. Implantable device and use therefor
US5714519A (en) 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
US5631347A (en) 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
US20010041786A1 (en) * 1995-06-07 2001-11-15 Mark L. Brader Stabilized acylated insulin formulations
US5700904A (en) 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
JPH11509195A (ja) 1995-06-30 1999-08-17 ノボ ノルディスク アクティーゼルスカブ 糖尿病の特徴を有する疾患の予防
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
AU718439B2 (en) 1995-09-21 2000-04-13 Genentech Inc. Human growth hormone variants
EP0856026A1 (de) 1995-10-19 1998-08-05 Receptagen Corporation Polyethylenglycolen mit diskreter länge
US5766620A (en) 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
FR2746035B1 (fr) 1996-03-15 1998-06-12 Microparticules de gel composite susceptibles d'etre utilisees comme vecteur(s) de principe(s) actif(s), l'un de leurs procedes de preparation et leurs applications
US5826633A (en) 1996-04-26 1998-10-27 Inhale Therapeutic Systems Powder filling systems, apparatus and methods
US6103270A (en) 1996-06-07 2000-08-15 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
US5948751A (en) 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
GB9613858D0 (en) 1996-07-02 1996-09-04 Cortecs Ltd Hydrophobic preparations
US5905140A (en) 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
ES2218622T3 (es) 1996-07-26 2004-11-16 Aventis Pharma Deutschland Gmbh Derivados de insulina con actividad de union al zinc incrementada.
US5856369A (en) 1996-07-30 1999-01-05 Osi Specialties, Inc. Polyethers and polysiloxane copolymers manufactured with double metal cyanide catalysts
DE19632440A1 (de) 1996-08-12 1998-02-19 Basf Ag Verfahren zur Herstellung von aus Polykationen aufgebauten, geformten Mischhydroxiden
US6180604B1 (en) 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
US5874111A (en) 1997-01-07 1999-02-23 Maitra; Amarnath Process for the preparation of highly monodispersed polymeric hydrophilic nanoparticles
US6011008A (en) 1997-01-08 2000-01-04 Yissum Research Developement Company Of The Hebrew University Of Jerusalem Conjugates of biologically active substances
US5830918A (en) 1997-01-15 1998-11-03 Terrapin Technologies, Inc. Nonpeptide insulin receptor agonists
EP1017408B1 (de) 1997-02-05 2005-04-13 F. Hoffmann-La Roche Ag Verwendung von tetrahydolipstatin in der behandlung von diabetes typ ii
US6043214A (en) 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US6310038B1 (en) 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
US5898028A (en) * 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
KR19980075132A (ko) * 1997-03-28 1998-11-05 민병무 중간사슬지방산(medium-chain fatty acids)을 유효성분으로 하는 치아우식증 및 치주질환 치료제용 의약조성물
PE79099A1 (es) 1997-06-13 1999-08-24 Lilly Co Eli Formulaciones de insulina estables
JPH1112177A (ja) 1997-06-25 1999-01-19 Teikoku Seiyaku Co Ltd 安定なアスピリン含有外用製剤
US6068993A (en) 1997-07-02 2000-05-30 Biobras Sa Vector for expression of heterologous protein and methods for extracting recombinant protein and for purifying isolated recombinant insulin
US20020115609A1 (en) 1997-07-14 2002-08-22 Hayat Onyuksel Materials and methods for making improved micelle compositions
KR20010022007A (ko) 1997-07-18 2001-03-15 추후보정 생물학적 활성 물질의 서방용 생분해성 마크로머
US6182712B1 (en) 1997-07-21 2001-02-06 Inhale Therapeutic Systems Power filling apparatus and methods for their use
GB9715444D0 (en) * 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
RU2117488C1 (ru) * 1997-07-30 1998-08-20 Институт нефтехимического синтеза им.А.В.Топчиева РАН Твердое инсулинсодержащее лекарственное средство
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
CN1276731A (zh) * 1997-10-24 2000-12-13 伊莱利利公司 不溶性胰岛素组合物
ATE243711T1 (de) * 1997-10-24 2003-07-15 Novo Nordisk As Aggregate von menschlichen insulinderivaten
US6444641B1 (en) * 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US5955459A (en) 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
CO4970787A1 (es) 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
KR100253916B1 (ko) 1997-12-29 2000-05-01 김충환 사람 인슐린 전구체의 제조방법
DE69924232D1 (de) * 1998-01-09 2005-04-21 Novo Nordisk As Stabilisierte insulin-zubereitungen
US6495514B1 (en) 1998-01-21 2002-12-17 Mercer University Method for reducing inflammation and inducing an analgesic effect and compounds thereof
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6192887B1 (en) * 1998-05-19 2001-02-27 The Pennsylvania State University Broad spectrum microbicidal and spermicidal compositions and methods having activity against sexually transmitted agents including papillomaviruses
US6257233B1 (en) 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
DE19825447A1 (de) 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
RU2205188C2 (ru) 1998-06-30 2003-05-27 Ново Нордиск А/С Затравочные кристаллы для получения пептидов или протеинов
US5968554A (en) 1998-07-07 1999-10-19 Cascade Development, Inc. A Subsidiary Of Cardinal Health, Inc. Sustained release pharmaceutical preparation
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
US20030049654A1 (en) 1998-10-16 2003-03-13 Xencor Protein design automation for protein libraries
JP2002529514A (ja) 1998-11-18 2002-09-10 ノボ ノルディスク アクティーゼルスカブ フェノール及びクレゾールを要さない安定なインスリン水性調製物
DK1146896T3 (da) * 1999-01-26 2002-09-02 Lilly Co Eli Formuleringer, som indeholder monodisperse hexamere acylerede insulin-analoger
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
JP2002537321A (ja) * 1999-02-22 2002-11-05 エラン コーポレイション ピーエルスィー 促進剤を含む固体経口剤形
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
DE19908041A1 (de) 1999-02-24 2000-08-31 Hoecker Hartwig Kovalent verbrückte Insulindimere
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6451974B1 (en) 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
US6630169B1 (en) 1999-03-31 2003-10-07 Nektar Therapeutics Particulate delivery systems and methods of use
US6444223B1 (en) 1999-05-28 2002-09-03 Alkermes Controlled Therapeutics, Inc. Method of producing submicron particles of a labile agent and use thereof
CA2376714A1 (en) 1999-06-11 2001-01-04 Shearwater Corporation Hydrogels derived from chitosan and poly(ethylene glycol) or related polymers
US6309633B1 (en) * 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
WO2001000654A2 (en) 1999-06-29 2001-01-04 Pharmaceutical Discovery Corporation Purification and stabilization of peptide and proteins in pharmaceutical agents
KR100345214B1 (ko) 1999-08-17 2002-07-25 이강춘 생체적합성 고분자가 수식된 펩타이드의 비점막 전달
US6323311B1 (en) 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
HU229310B1 (en) 1999-10-29 2013-10-28 Nektar Therapeutics Dry powder compositions having improved dispersivity
AU2001220765A1 (en) 2000-01-24 2001-07-31 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
CN1312080A (zh) * 2000-02-18 2001-09-12 日本脏器制药株式会社 含有脂肪酸的组合物
WO2002000207A1 (en) 2000-06-27 2002-01-03 Mi Tech Company Limited The controlled release preparation of insulin and its method
US6479065B2 (en) 2000-08-10 2002-11-12 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
EP2316490A3 (de) 2000-10-31 2012-02-01 PR Pharmaceuticals, Inc. Verfahren und Formulierungen zur verbesserten Abgabe von bioaktiven Molekülen
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
HUP0500733A3 (en) 2001-02-09 2010-01-28 Genentech Inc Crystallization of igf-1
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US6558702B2 (en) 2001-04-13 2003-05-06 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
OA13136A (en) * 2001-05-21 2006-12-13 Nektar Therapeutics Pulmonary administration of chemically modified insulin.
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US20030040601A1 (en) 2001-06-08 2003-02-27 Ivan Diers Method for making insulin precursors and insulin analog precursors
PE20030536A1 (es) * 2001-09-07 2003-07-03 Biocon Ltd Metodos para sintetizar conjugados polipeptido de insulina-oligomero, y conjugados polipeptido de proinsulina-oligomero y metodos de sintetizar dichos conjugados
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) * 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
CN1170851C (zh) * 2001-09-27 2004-10-13 华中科技大学 治疗糖尿病的口服药脂肪二酰氨基酸胰岛素及其合成方法
AU2002360549A1 (en) 2001-12-10 2003-06-23 Spherics, Inc. Methods and products useful in the formation and isolation of microparticles
AU2002363998A1 (en) 2001-12-15 2003-06-30 Spherics, Inc. Bioadhesive drug delivery system with enhanced gastric retention
CA2471096A1 (en) * 2001-12-19 2003-07-03 Alza Corporation Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
WO2004060347A2 (en) 2002-09-03 2004-07-22 Transform Pharmaceuticals, Inc. Pharmaceutical propylene glycol solvate compositions
WO2003086361A1 (en) 2002-04-18 2003-10-23 Dr. Reddy's Laboratories Ltd. Rapidly dispersing solid oral compositions
CN1665540A (zh) 2002-07-09 2005-09-07 桑多斯股份公司 含1,2－丙二醇的高浓度人生长激素液体制剂
DE10250297A1 (de) 2002-10-29 2004-05-19 Aventis Pharma Deutschland Gmbh Kristalle von Insulinanaloga und Verfahren zu ihrer Herstellung
US20040235948A1 (en) * 2003-03-05 2004-11-25 Solvay Pharmaceuticals Gmbh Treatment of diabetic patients with omega-3-fatty acids
JP2006520335A (ja) * 2003-03-18 2006-09-07 ノバルティス アクチエンゲゼルシャフト 脂肪酸とアミノ酸を含有する組成物
WO2005016312A1 (en) * 2003-08-13 2005-02-24 Nobex Corporation Micro-particle fatty acid salt solid dosage formulations for therapeutic agents
WO2005034874A2 (en) * 2003-10-08 2005-04-21 The Mclean Hospital Corporation Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
EP1701714A2 (de) * 2004-01-07 2006-09-20 Nektar Therapeutics Verbesserte zusammensetzungen mit verzögerter freisetzung für die pulmonale verabreichung von insulin
EP1570752B1 (de) * 2004-03-06 2008-07-02 Cognis IP Management GmbH Use of unsaturated fatty acids for the reduction of appetite or food intake

Also Published As

Publication number Publication date
EP2626368A3 (de) 2013-10-16
EP2626368A2 (de) 2013-08-14
AU2005269753B2 (en) 2011-08-18
JP5750494B2 (ja) 2015-07-22
NZ553263A (en) 2010-06-25
UA91512C2 (ru) 2010-08-10
AU2005269753A1 (en) 2006-02-09
WO2006014673A3 (en) 2006-08-17
US20060019874A1 (en) 2006-01-26
RU2007105824A (ru) 2008-08-27
US9102758B2 (en) 2015-08-11
BRPI0513508A (pt) 2008-05-06
PT2626368T (pt) 2017-03-10
NO20070859L (no) 2007-04-12
JP5220410B2 (ja) 2013-06-26
JP5721266B2 (ja) 2015-05-20
IL209494A (en) 2015-07-30
US9101596B2 (en) 2015-08-11
CN103223160A (zh) 2013-07-31
EP1773878A2 (de) 2007-04-18
US7872095B2 (en) 2011-01-18
US7875700B2 (en) 2011-01-25
CN105801686A (zh) 2016-07-27
CN101027318B (zh) 2016-05-25
CN105801686B (zh) 2020-04-07
IL180762A (en) 2015-06-30
US7605123B2 (en) 2009-10-20
NO345613B1 (no) 2021-05-10
JP2014043470A (ja) 2014-03-13
US20110118179A1 (en) 2011-05-19
MX2007000883A (es) 2007-04-02
KR101276754B1 (ko) 2013-06-19
JP2008506782A (ja) 2008-03-06
PL1773878T3 (pl) 2015-07-31
RU2527893C2 (ru) 2014-09-10
EP2626368B1 (de) 2016-12-21
DK2626368T3 (en) 2017-02-27
RU2010105921A (ru) 2011-08-27
IL209494A0 (en) 2011-01-31
NO340825B1 (no) 2017-06-26
DK1773878T3 (en) 2015-05-11
KR101309770B1 (ko) 2013-09-30
US8563685B2 (en) 2013-10-22
HK1187826A1 (en) 2014-04-17
US20100105605A1 (en) 2010-04-29
ES2535823T3 (es) 2015-05-18
CA2910494C (en) 2018-10-23
CA2910494A1 (en) 2006-02-09
AU2005269753A2 (en) 2006-02-09
US20110124553A1 (en) 2011-05-26
CA2580313A1 (en) 2006-02-09
PL2626368T3 (pl) 2017-06-30
JP2011236233A (ja) 2011-11-24
CN103223160B (zh) 2015-02-18
WO2006014673A2 (en) 2006-02-09
RU2393168C2 (ru) 2010-06-27
NO20170341A1 (no) 2007-01-22
IL180762A0 (en) 2007-06-03
KR20070059060A (ko) 2007-06-11
EP1773878A4 (de) 2012-06-20
CN101027318A (zh) 2007-08-29
PT1773878E (pt) 2015-06-05
IL227117A (en) 2017-02-28
EP1773878B1 (de) 2015-03-04
CA2580313C (en) 2016-03-15
US20060019873A1 (en) 2006-01-26
KR20120120985A (ko) 2012-11-02
UA103758C2 (ru) 2013-11-25
ZA200701446B (en) 2008-09-25
ES2618028T3 (es) 2017-06-20
US20060018874A1 (en) 2006-01-26

Similar Documents

Publication Publication Date Title
BRPI0513508B1 (pt) Conjugados de insulina-oligômero, formulações e usos desses
AU2014200247B2 (en) Insulin-oligomer conjugates, formulations and uses thereof

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/07/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2732 DE 16-05-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.